KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Clin Cancer ResPMID 34158360PMC94014852021-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.Am J HematolPMID 34161631无 PMCID2021-Oct-010.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.Clin Cancer ResPMID 34301751PMC96629112021-Oct-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.J Clin OncolPMID 34343033PMC84784032021-Oct-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.JAMA OncolPMID 34351356PMC83435042021-Oct-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.J Clin OncolPMID 34357781PMC84783862021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.J Clin OncolPMID 34379442无 PMCID2021-Oct-010.95The trial is an oncology randomized Phase III with a primary cognitive function endpoint and OS as a secondary time-to-event endpoint. However, the intervention is a radiation technique comparison (prophylactic cranial irradiation with or without hippocampal avoidance), not a drug-containing intervention. Therefore, it does not meet the drug-intervention criterion for inclusion.待处理
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.JAMA OncolPMID 34383006PMC85319922021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.JAMA DermatolPMID 34406366PMC83747432021-Oct-010.98未发现恶性肿瘤人群证据。待处理
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.JAMA OncolPMID 34436523PMC83917722021-Oct-010.95The study is a Phase III randomized oncology trial with a drug intervention, but the primary endpoint is a cardiac safety/efficacy measure (subclinical myocardial impairment), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the eligibility criterion for a primary/key secondary time-to-event efficacy endpoint.待处理
Short-term Outcomes of Robotic Gastrectomy vs Laparoscopic Gastrectomy for Patients With Gastric Cancer: A Randomized Clinical Trial.JAMA SurgPMID 34468701PMC84113612021-Oct-010.93干预为非药物单独策略,未满足药物干预要求。待处理
A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.CorneaPMID 34481407PMC84231422021-Oct-010.98未发现恶性肿瘤人群证据。待处理
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Blood Cancer JPMID 34599139PMC84868172021-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study.Eur J DermatolPMID 34789441无 PMCID2021-Oct-010.98未发现恶性肿瘤人群证据。待处理
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.J Manag Care Spec PharmPMID 34595948PMC103911152021-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".OphthalmologyPMID 31668888无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.Ther Apher DialPMID 33200512PMC84518842021-Oct0.98未发现恶性肿瘤人群证据。待处理
Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.Ther Apher DialPMID 33340238PMC84519042021-Oct0.98未发现恶性肿瘤人群证据。待处理
Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.Ophthalmol RetinaPMID 33373715PMC82333982021-Oct0.98未发现恶性肿瘤人群证据。待处理
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.Ann Surg OncolPMID 33641012PMC79140392021-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.J Diabetes InvestigPMID 33751849PMC85049012021-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.Br J DermatolPMID 33763874PMC85188772021-Oct0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.Cancer Res TreatPMID 33781053PMC85240252021-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.OphthalmologyPMID 33798654无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.CephalalgiaPMID 33939497PMC85044132021-Oct0.98未发现恶性肿瘤人群证据。待处理
Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.Am J OphthalmolPMID 33945820无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
The HELENA study: Hexvix®-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study.World J UrolPMID 34002265PMC85215132021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases.SurgeryPMID 34030885无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.J UrolPMID 34039013无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.Clin Pharmacol TherPMID 34048027PMC84498012021-Oct0.45While the record describes an oncology, human, randomized, Phase III drug trial, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It is a pharmacogenomic subgroup analysis of SNP-treatment interactions, not a primary efficacy result report. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort.待处理
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.Clin Lymphoma Myeloma LeukPMID 34059488PMC85281792021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.J Eur Acad Dermatol VenereolPMID 34076919无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.Lancet Infect DisPMID 34081923无 PMCID2021-Oct0.85The study is a phase 3 randomized trial in oncology (HPV vaccines to prevent cancer) with a drug intervention, but the primary endpoint is immunogenicity (antibody persistence) and correlation with efficacy against persistent infections, not a standard time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis.待处理
Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.J Bone Miner ResPMID 34101900PMC85970972021-Oct0.98未发现恶性肿瘤人群证据。待处理
The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial.ChestPMID 34102142无 PMCID2021-Oct0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).OncologistPMID 34105207PMC84888002021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.Diabetes Obes MetabPMID 34121308无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms.JCO Oncol PractPMID 34125586PMC98101432021-Oct0.95The study is a randomized Phase III trial with a primary endpoint (patient-reported Likert scale) but lacks a drug intervention (it tests consent forms) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).待处理
Acute and Chronic Placental Abnormalities in a Multicenter Cohort of Newborn Infants with Hypoxic-Ischemic Encephalopathy.J PediatrPMID 34144032PMC130103752021-Oct0.98未发现恶性肿瘤人群证据。待处理
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).GastroenterologyPMID 34144047无 PMCID2021-Oct0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.Diabetes Obes MetabPMID 34169625无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.Epilepsy ResPMID 34246118无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.Future OncolPMID 34254530无 PMCID2021-Oct0.45The record describes the protocol/design of a Phase III randomized oncology trial and an early biomarker study within it. It does not report the primary or secondary time-to-event efficacy outcomes (survival, progression, etc.) required for inclusion in a Kaplan-Meier digitization cohort.待处理
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.J Thromb HaemostPMID 34255420无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.LeukemiaPMID 34274940PMC87440702021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.Expert Rev Anticancer TherPMID 34281470无 PMCID2021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.Br J HaematolPMID 34331348PMC92928942021-Oct0.95The report describes a randomized, placebo-controlled Phase III trial of a drug (fedratinib) in oncology (myelofibrosis), but the primary efficacy endpoints are response rates (spleen volume response, symptom response), which are categorical, not time-to-event. There is no explicit mention of overall survival, progression-free survival, or any other time-to-event endpoint in the provided abstract.待处理
IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.Pediatr NeurolPMID 34339951无 PMCID2021-Oct0.98未发现恶性肿瘤人群证据。待处理
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.CPT Pharmacometrics Syst PharmacolPMID 34346168PMC85207482021-Oct0.98未发现恶性肿瘤人群证据。待处理
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.Gynecol OncolPMID 34353615PMC95551192021-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理